1. "2015"
Formats
  1. Journal Article (2716)
  2. Meeting Abstract (1680)
  3. Book Section (364)
  4. Conference Paper (26)
  5. Book Whole (19)
  6. Review (2)
  7. Research Letter (1)
Groups
  1. Department of Medicine (1855)
  2. GSK Faculty (1116)
  3. Solid Tumor Oncology Division (1035)
  4. Surgery (883)
  5. Survivorship Research (752)
  6. Center for Hematologic Malignancies (746)

More Groups

People
  1. William Travis (102)
  2. Michael Berger (96)
  3. Clifford Hudis (85)
  4. Marc Ladanyi (79)
  5. Jedd Wolchok (68)
  6. Britta Weigelt (67)

More People

Years
  1. 2015 (4808)
Publications
  1. Journal of Clinical Oncology (475)
  2. Blood (224)
  3. Cancer Research (168)
  4. Modern Pathology (125)
  5. Laboratory Investigation (112)
  6. International Journal of Radiation Oncology, Biology, Physics (91)

More Publications

Publishers
  1. Elsevier Inc. (581)
  2. American Society of Clinical Oncology (508)
  3. Springer (380)
  4. Nature Publishing Group (301)
  5. American Association for Cancer Research (263)
  6. American Society of Hematology (228)

More Publishers

Results (4808)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II trial of everolimus (E) and bevacizumab (B) in advanced non-clear cell renal cell cancer (ncRCC) to show efficacy in patients (pts) with papillary features
    Meeting Abstract

    Voss, M. H.; Chen, Y. B.; Chaim, J.; Coskey, D. T.; Woo, K.; Redzematovic, A.; Wang, P.; Lee, W.; Patil, S.; Molina, A. M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • The DART Study: A phase 2 randomized double-blind study of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma (RCC)
    Meeting Abstract

    Voss, M. H.; Plimack, E. R.; Rini, B. I.; Atkins, M. B.; Alter, R.; Bhatt, R. S.; Beck, J. T.; Mutyaba, M.; Pappas, K. M.; Wilson, D.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Randomized phase 2 study to assess the safety and efficacy of CRLX101 in combination with bevacizumab in patients (pts.) with metastatic renal cell carcinoma (RCC) versus standard of care (SOC)
    Meeting Abstract

    Voss, M. H.; Coates, A.; Garmey, E. G.; Haas, N. B.; Hutson, T.; Keefe, S. M.; Motzer, R.; Piscitelli, A.; Vogelzang, N. J.; Figlin, R. A.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Risk-based treatment for synovial sarcoma in patients under 30 years of age: Children's Oncology Group study ARST0332
    Meeting Abstract

    Venkatramani, R.; Anderson, J. R.; Million, L.; Coffin, C. M.; McCarville, B.; Randall, R. L.; Parham, D.; Kao, S. C.; Hayes-Jordan, A. A.; Wolden, S. L.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Prospective identification of potentially actionable molecular alterations in cancers of unknown primary
    Meeting Abstract

    Varghese, A. M.; Hyman, D. M.; Zehir, A.; Vakiani, E.; Klimstra, D. S.; Ladanyi, M.; Berger, M. F.; Solit, D. B.; Saltz, L.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • A phase 2 study (2-stage, 2-cohort) of the oral PARP inhibitor talazoparib (BMN 673) in patients with germline BRCA mutation and locally advanced and/or metastatic breast cancer (ABRAZO)
    Meeting Abstract

    Turner, N. C.; Balmana, J.; Fasching, P. A.; Hurvitz, S. A.; Telli, M. L.; Visco, F.; Wardley, A. M.; Zhang, C.; Lokker, N. A.; Lounsbury, D. L.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR plus triplenegative breast cancer (TNBC)
    Meeting Abstract

    Traina, T. A.; Miller, K.; Yardley, D. A.; O'Shaughnessy, J.; Cortes, J.; Awada, A.; Kelly, C. M.; Trudeau, M. E.; Schmid, P.; Gianni, L.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Re-exposure to blinatumomab after CD19-positive relapse: Experience from three trials in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (R/R ALL)
    Meeting Abstract

    Topp, M. S.; Stelljes, M.; Zugmaier, G.; Barnette, P.; Heffner, L. T.; Trippett, T. M.; Bargou, R. C.; Holland, C.; Benjamin, J.; Litzow, M. R.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • A phase Ib study of abemaciclib with therapies for metastatic breast cancer
    Meeting Abstract

    Tolaney, S. M.; Beeram, M.; Beck, J. T.; Conlin, A. K.; Dees, E. C.; Dickler, M. N.; Helsten, T. L.; Conkling, P. R.; Edenfield, W. J.; Richards, D. A.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase I studies of anti-ENPP3 antibody drug conjugates (ADCs) in advanced refractory renal cell carcinomas (RRCC)
    Meeting Abstract

    Thompson, J. A.; Motzer, R.; Molina, A. M.; Choueiri, T. K.; Heath, E. I.; Kollmannsberger, C. K.; Redman, B. G.; Sangha, R. S.; Ernst, D. S.; Pili, R.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save